TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value of $9.63 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-03-17
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $15.65.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2021 was $9.63.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2019 was $15.65.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-12-31 | $9.63 10-K · filed 2022-03-17 | |||
| 2019-12-31 | $15.65 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $15.65 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $15.65 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $15.65 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |